Hear What Previous Attendees Have to Say
Hear from attendees across all previous editions of the Cell Therapy for Autoimmune Disease Summit and learn what they found most valuable in attending.
“The rapid and remarkable expansion of research in the use of cell therapy to treat autoimmune diseases has revealed the great potential for these novel approaches to transform the lives of patients with these challenging diseases.”
University of Pennsylvania
“Cell therapies for autoimmune diseases have entered a new phase in 2026 with promising clinical data and recent approvals across multiple modalities including T regulatory, CAR-T, and in vivo engineered cell therapies. It is an exciting time to focus on autoimmune disease.”
Immuthera / PolTREG
“A lot of new fascinating efficacy data in autoimmune diseases detailing the progress the industry has made. This also allowed for transparent panel talks and Q&A sessions.”
Thermo Fisher Scientific
“It was very nice to have active leaders in the CAR-T space share their learnings and challenges in an open forum with an emphasis on collaboration. Well done to create an open exchange of ideas.”
TG Therapeutics, Inc.
“The conference had a great set of attendees from academia, biotech and large pharma. This facilitated progressive and open discussion during talks, panels and roundtables.”
Cabaletta Bio
“It was great to hear different perspectives from leaders within our industry. It provided strategic thinking beyond data perceptions.”
Novartis
“The collaborative environment across company representatives. The presentations were more like discussions.”
Bristol Myers Squibb
“Everyone in the meeting is willing to share their knowledge and ask many critical questions in the field, which in turn inspire other people to further understand the unmet needs in the future.”
Legend Biotech
“I learned an incredible amount about the space from the summit. It was helpful to hear perspectives from investors, physicians, and researchers in one space. It was also really helpful to hear about the collective challenges that all of the research teams were facing.”
Sanguine Biosciences
“It attracted a lot of the top companies and researchers in the field and the atmosphere was very supportive and open for discussions. Good contacts were made and important questions were raised. There was time and opportunity to meet people and find common interests.”
The University of Tennessee Health Science Center
“This specific meeting addresses the CAR-T development concerns in autoimmune disease. Also, it is a small enough meeting to be able to network and meet others in the same space.”
Legend Biotech
“The ability for networking, the novelty of data, and the extremely important topics that were presented during the meeting!”
Cleveland Clinic
“It was a nice mix of larger and small biotech companies/presentations, and I really enjoyed that the size of the conference was small enough to have meaningful conversations.”
Kite Pharma
“I am excited to attend the Cell Therapy for Autoimmune Disease Summit as I believe cellular therapies are an exciting addition to treatments of lupus and other autoimmune diseases.”
Medical University of South Carolina
“Beyond my expectation, I could connect a lot of people who have engaged in the field in clinical or pharma, biotech, academia. This was a really important experience to make a strong relationships and network in the field.”
ONO Pharmaceutical Co.